Cencora, Inc. (BST:ABG)
Germany · Delayed Price · Currency is EUR | Market Cap | 52.90B +11.9% |
| Revenue (ttm) | 291.27B +5.1% |
| Net Income | 2.30B +38.3% |
| EPS | 11.78 +39.1% |
| Shares Out | n/a |
| PE Ratio | 23.02 |
| Forward PE | 16.44 |
| Dividend | 2.01 (0.73%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 281.40 |
| Day's Range | n/a |
| 52-Week Range | 216.40 - 325.35 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
Cencora price target raised to $346 from $342 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cencora (COR) to $346 from $342 and keeps an Overweight rating on the shares.
Cencora price target raised to $370 from $340 at Baird
Baird raised the firm’s price target on Cencora (COR) to $370 from $340 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and…
Cencora price target raised to $430 from $412 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Cencora (COR) to $430 from $412 and keeps a Buy rating on the shares.
Cencora price target raised to $350 from $330 at Evercore ISI
Evercore ISI raised the firm’s price target on Cencora (COR) to $350 from $330 and keeps an Outperform rating on the shares.
Cencora price target raised to $370 from $355 at Citi
Citi raised the firm’s price target on Cencora (COR) to $370 from $355 and keeps a Buy rating on the shares. The firm views the company’s earnings report as solid.
Cencora Earnings Call Transcript: Q3 2026
Q3 saw strong double-digit adjusted operating income and EPS growth, driven by specialty and MSO performance, the OneOncology acquisition, and robust capital deployment. Fiscal 2026 guidance was raised, with continued momentum expected across U.S. and international segments.
Cencora Earnings release: Q3 2026
Cencora released its Q3 2026 earnings on August 5, 2026, summarizing the period's financial results.
Cencora Slides: Q3 2026
Cencora has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 5, 2026.
Cencora Quarterly report: Q3 2026
Cencora has published its Q3 2026 quarterly earnings report on August 5, 2026.
Cencora lifts annual profit view on strong demand for specialty medicines
U.S. drug distributor Cencora raised its annual adjusted profit forecast on Wednesday after quarterly results beat Wall Street expectations, driven by strong demand for specialty medicines.
Cencora reports Q3 adjusted EPS $4.48, consensus $4.35
Reports Q3 revenue $84.8B, consensus $84.15B. “Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members. Our strong performanc...
Cencora raises FY26 adjusted EPS view to $17.75-$17.95 from $17.70-$17.90
FY26 consensus $17.78. Sees FY26 revenue growth 4%-6%, consensus $336.89B.
Cencora Reports Fiscal 2026 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On...
FTC takes closer look at Cencora-Covetrus animal health merger, Bloomberg News reports
The U.S. Federal Trade Commission is taking a closer look at a proposed $3.5 billion acquisition that would combine two of the leading national suppliers of veterinary products, Cencora's MWI Anima...
Cencora price target raised to $310 from $285 at BofA
BofA raised the firm’s price target on Cencora (COR) to $310 from $285 and keeps a Neutral rating on the shares. The firm is applying a higher target multiple to…
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the openi...
Cencora price target raised to $285 from $280 at BofA
BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $280 and keeps a Neutral rating on the shares. At the firm’s Healthcare conference last…
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help spec...
Cencora names Samantha Hammock as Chief Human Resources Officer
Cencora (COR) “announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer, has announced she will retire from the company following a distinguished seven-year tenure....
Suncrete, Inc. Completes Arkansas Acquisition
Company Enhances Scale and Expands Footprint into New Markets TULSA, Okla., June 15, 2026 /PRNewswire/ -- Suncrete, Inc. (Nasdaq: RMIX) ("Suncrete" or the "Company"), a ready-mix concrete logistics an...
Cencora Announces Samantha Hammock as Chief Human Resources Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire f...
Cencora price target lowered to $350 from $425 at Barclays
Barclays lowered the firm’s price target on Cencora (COR) to $350 from $425 and keeps an Overweight rating on the shares. The firm updated estimates and targets in the drug…
Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell ...
Cencora appoints Eva Boratto as CFO
Cencora (COR) appointed Eva Boratto EVP and CFO, effective June 29. Boratto succeeds James Cleary, who will be retiring from his role as EVP and CFO as previously announced. Cleary…